Caelum Biosciences, Inc.

13 articles with Caelum Biosciences, Inc.

• Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

  9/29/2021

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), and a company it founded, Caelum Biosciences, Inc. (“Caelum”), today announced that AstraZeneca’s Alexion notified Caelum that it has exercised its option to acquire Caelum.

• 

  AstraZeneca Buys Caelum BioSciences in $500 Million Deal

  9/29/2021

  AstraZeneca’s Alexion plans to buy all remaining equity in Caelum Biosciences and pick up Caelum’s CAEL-101 in the process.

• Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

  6/11/2021

  Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response

• Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

  5/12/2021

  Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, have been accepted for e-poster presentation at the European Hematology Association (EHA) Congress 2021, taking place virtually from June 9 to 17, 2021

• Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

  3/1/2021

  Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today announced its collaboration with and support of the amyloidosis advocacy community as Amyloidosis Awareness Month begins

• Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

  11/4/2020

  Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5 to 8, 2020

• Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

  9/14/2020

  Sept. 14, 2020 12:00 UTC - Phase 2 study met primary objective, supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients - - Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78% at 37 months) and durable organ response - BOSTON & BORDENTOWN, N.J.--( BUSINESS WIRE )-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Caelum Bios

• Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis

  1/31/2019

  Collaboration provides opportunity to diversify Alexion’s clinical-stage rare hematology portfolio

• Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals

  1/31/2019

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Caelum Biosciences, Inc. (“Caelum”) has signed a strategic agreement with Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ: ALXN) to advance the development of CAEL-101 for light chain (AL) amyloidosis.

• 

  Alexion Strikes Development Deal With Caelum Biosciences in Rare Systemic Disorder

  1/31/2019

  Shares of Fortress Biotech have skyrocketed more than 62 percent in premarket trading after its subsidiary Caelum Biosciences forged a deal worth up to more than $500 million with Alexion Pharmaceuticals.

• Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting

  12/12/2017

  Columbia University reports Caelum Biosciences’ CAEL-101 was well tolerated, demonstrated early and clinically efficacious organ response in Phase 1a/1b trial in AL amyloidosis.

• Caelum Biosciences Announces Positive Phase Ia/Ib Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

  12/11/2017

  Caelum in-licensed CAEL-101 from Columbia and recently completed a Phase 1a/1b clinical trial at Columbia for the treatment of AL amyloidosis.

• Fortress Biotech Announces Filing Of Provisional Patent Application For Caelum Biosciences' CAEL-101

  7/17/2017